NCT03569891: A reported trial by CSL Behring
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03569891 |
|---|---|
| Title | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 27, 2018 |
| Completion date | Sept. 22, 2021 |
| Required reporting date | Sept. 22, 2022, midnight |
| Actual reporting date | Aug. 15, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |